Search Results - "Hansen, A.R."

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors by Chen, T.W., Razak, A.R., Bedard, P.L., Siu, L.L., Hansen, A.R.

Get full text

Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium by Stukalin, I, Wells, J C, Graham, J, Yuasa, T, Beuselinck, B, Kollmansberger, C, Ernst, D S, Agarwal, N, Le, T, Donskov, F, Hansen, A R, Bjarnason, G A, Srinivas, S, Wood, L A, Alva, A S, Kanesvaran, R, Fu, S Y F, Davis, I D, Choueiri, T K, Heng, D Y C

“…In the present study, we explored the real-world efficacy of the immuno-oncology checkpoint inhibitor nivolumab and the tyrosine kinase inhibitor cabozantinib…”
Get full text

2863 A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer by Oosting, S.F, Chen, T.W.W, Huang, S.H.H, Wang, L, Waldron, J, Gilbert, R, Goldstein, D.P, Halmos, G.B, Witjes, M.J.H, Gietema, J.A, O'Sullivan, B, Langendijk, J.A, Siu, L.L, Hansen, A.R

Get full text

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review by Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L.L., Hansen, A.R.

“…Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or…”
Get full text

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study by Hansen, A.R., Massard, C., Ott, P.A., Haas, N.B., Lopez, J.S., Ejadi, S., Wallmark, J.M., Keam, B., Delord, J.-P., Aggarwal, R., Gould, M., Yang, P., Keefe, S.M., Piha-Paul, S.A.

“…Patients with castration-resistant prostate cancer derive only modest clinical benefit from available therapies. Blockade of the inhibitory programmed death 1…”
Get full text

3P Beyond first-line therapy in metastatic adrenal cortical cancer (ACC): Is it time to move on from chemotherapy? by Mittal, A., Amer, L., Ayodele, O., Radi, S., Li, X., Mete, O., Pasternak, J., Jiang, D.M., Kumar, V., Hansen, A.R.

Get full text

1754P Association between body mass index (BMI) and anti-PD1/L1 immune checkpoint inhibitor (ICI) outcomes in patients with metastatic urothelial carcinoma (mUC) by Labidi, S., N. Meti, R. Barua, Riromar, J.J., Hansen, A.R., Jiang, D.M., Fallah-Rad, N., Sridhar, S., Ferrario, C., Pezo, R., Cheng, S., Sacher, A., Rose, A.

Get full text

1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients by Zhao, E.Y., Sanz Garcia, E., Liu, Z., Marsh, K., Abdul Razak, A., Spreafico, A., Bedard, P.L., Hansen, A.R., Lheureux, S., Torti, D., Lam, B., Pugh, T.J., Siu, L.L.

Get full text

114P Changes in serum choline (Ch) levels to predict treatment outcomes in advanced cancer patients (pts) treated with immunotherapy (IO) by Garcia, E. Sanz, Genta, S., Liu, Z., Razak, A.R. Abdul, Hansen, A.R., Spreafico, A., Zhang, W., Chen, E., Siu, L.L., Bedard, P.

Get full text

541P Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours by Hussein, M., Percent, I., Arrowsmith, E., Arkenau, H-T., Chu, Q., Hansen, A.R., Erzen, D., Qiu, S., Lucarelli, A., Ulahannan, S.

Get full text

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial) by Spreafico, A., Heirali, A.A., Araujo, D.V., Tan, T.J., Oliva, M., Schneeberger, P.H.H., Chen, B., Wong, M.K., Stayner, L.-A., Hansen, A.R., Saibil, S.D., Wang, B.X., Cochrane, K., Sherriff, K., Allen-Vercoe, E., Xu, W., Siu, L.L., Coburn, B.

“…The intestinal microbiome has been associated with response to immune checkpoint inhibitors (ICIs) in humans and causally implicated in ICI responsiveness in…”
Get full text

1367P JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study by Calvo, E., Doger de Spéville, B., Carles Galceran, J., Peer, A., Sarid, D.L., Eigl, B.J., Avadhani, A., Yao, D., Lin, V., Wu, S., Jaiprasart, P., Loffredo, J., Tamegnon, M., Xie, H., Hansen, A.R.

Get full text

1455P Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC) by Takemura, K., Navani, V., Ernst, M.S., Wells, J.C., Choueiri, T.K., Meza, L., Pal, S.K., Lee, J-L., Li, H., Agarwal, N., Alva, A.S., Hansen, A.R., Basappa, N.S., Szabados, B.E., Powles, T.B., Tran, B., Hocking, C.M., Beuselinck, B., Yuasa, T., Heng, D.Y.C.

Get full text

546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158 by O'Malley, D., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus-Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Yao, L., Gozman, A., Jin, F.J., Maio, M.

Get full text

1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH by Hansen, A.R., Probst, S., Tutrone, R.F., Osman, M.M., Delpassand, E.S., Nordquist, L.T., Viglianti, B.L., Michalski, J.M., Beauregard, J-M., Oz, O.K., Courtney, K., Jensen, J., Wu, W., Fleshner, N., Sartor, O., Chi, K.N., Tagawa, S.T.

Get full text

Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC) by Voss, M.H., Azad, A.A., Hansen, A.R., Gray, J.E., Welsh, S.J., Achour, I., Hu, H., Lewis, L., Walcott, F.L., Oosting, S.F.

Get full text

1755PD - Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events by Veitch, Z.W., Shepshelovich, D., Gallagher, C., Wang, L., Razak, A.A., Spreafico, A., Bedard, P., Siu, L.L., Minasian, L., Hansen, A.R.

“…The goal of phase I trials is to determine adverse event (AE) profiles of new therapies. Typically, AEs are captured by clinicians, yet patient reported…”
Get full text

1269P - Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC) by Voss, M.H., Azad, A.A., Hansen, A.R., Gray, J.E., Welsh, S.J., Achour, I., Hu, H., Lewis, L., Walcott, F.L., Oosting, S.F.

“…MEDI0680 is a humanised IgG4κ anti-programmed cell death-1 (PD-1) mAb. We hypothesised that simultaneous blockade of PD-1:PD-L1/PD-L2 with MEDI0680 (M) and…”
Get full text

Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events by Veitch, Z.W., Shepshelovich, D., Gallagher, C., Wang, L., Razak, A.A., Spreafico, A., Bedard, P., Siu, L.L., Minasian, L., Hansen, A.R.

Get full text

795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158 by O'Malley, D., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Xu, L., Jin, F., Norwood, K., Maio, M.

Get full text